Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Authors

Jason Aldred, Selkirk Neurology and Inland Northwest Research
Eric Freire-Alvarez, Hospital General Universitario de Elche
Alexander V. Amelin, Pavlov First State Medical University of St. Petersburg
Angelo Antonini, University of Padua
Bruno Bergmans, General Hospital St. Jan
Filip Bergquist, University of Gothenburg
Manon Bouchard, Clinique Neuro-Lévis
Kumar Budur, AbbVie
Camille Carroll, Peninsula Medical School
K. Ray Chaudhuri, King's College London
Susan R. Criswell, Washington University St. Louis
Erik H. Danielsen, Aarhus University
Florin Gandor, Movement Disorders Hospital
Jia Jia, AbbVie
Thomas E. Kimber, Royal Adelaide Hospital
Hideki Mochizuki, Osaka University
Weining Z. Robieson, AbbVie
Amy M. Spiegel, AbbVie
David G. Standaert, University of Alabama at Birmingham
Saritha Talapala, AbbVie
Maurizio F. Facheris, AbbVie
Victor S.C. Fung, University of Sydney

ORCID

• Camille Carroll: 0000-0001-7472-953X

DOI

10.1007/s40120-023-00554-w

Publication Date

2023-10-10

Embargo Period

2024-03-14

Recommended Citation

Aldred, J., Freire-Alvarez, E., Amelin, A., Antonini, A., Bergmans, B., Bergquist, F., Bouchard, M., Budur, K., Carroll, C., Chaudhuri, K., Criswell, S., Danielsen, E., Gandor, F., Jia, J., Kimber, T., Mochizuki, H., Robieson, W., Spiegel, A., Standaert, D., Talapala, S., Facheris, M., & Fung, V. (2023) 'Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study', Available at: 10.1007/s40120-023-00554-w